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Abstract
Objective: Patients with heart failure and ischaemic heart disease may obtain benefit from revascularisation if viable dysfunctional 
myocardium is present. Such patients have an increased operative risk, so it is important to ensure that viability is correctly identified. 
In this study, we have compared the utility of 3 imaging modalities to detect myocardial scar.
Design: Prospective, descriptive study.
Setting: Tertiary cardiac centre.
Patients: 35 patients (29 male, average age 70 years) with coronary artery disease and symptoms of heart failure (NYHA class II).
Intervention: Assessment of myocardial scar by 99Tc-Sestamibi (MIBI), 18F-flurodeoxyglucose (FDG) and cardiac magnetic resonance 
(CMR).
Outcome Measure: The presence or absence of scar using a 20-segment model.
Results: More segments were identified as nonviable scar using MIBI than with FDG or CMR. FDG identified the least number of scar 
segments per patient (7.4 +/- 4.8 with MIBI vs. 4.9 +/- 4.2 with FDG vs. 5.8 +/- 5.0 with CMR, p = 0.0001 by ANOVA). The strongest 
agreement between modalities was in the anterior wall with the weakest agreement in the inferior wall. Overall, the agreement between 
modalities was moderate to good.
Conclusion: There is considerable variation amongst these 3 techniques in identifying scarred myocardium in patients with coronary 
disease and heart failure. MIBI and CMR identify more scar than FDG. We recommend that MIBI is not used as the sole imaging 
modality in patients undergoing assessment of myocardial viability.
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Introduction
Coronary artery disease is the most common cause of 
heart failure in the Western world.1–3 It is increasingly 
recognised that myocardium, which was once thought 
to be irreversibly damaged, may recover function and 
hence improve prognosis and symptoms in selected 
patients  who  undergo  revascularisation  in  addition 
to  optimal  medical  management.4  Clinically,  this 
relies  on  myocardial  viability  assessment  using 
imaging  techniques.  Decisions  regarding  high  risk 
revascularisation also need to be made, sometimes 
urgently,  when  patients  presenting  in  NYHA  class 
3/4  heart  failure  have  significant  left  ventricular 
dysfunction and coronary artery disease yet do not 
have a history of limiting angina.
Patients  with  impaired  left  ventricular  function 
represent a higher operative risk group than patients 
with  normal  LV  function.  Recent  reports  indicate 
that  the  perioperative  mortality  after  CABG  in 
patients  with  advanced  LV  dysfunction  varies 
between  2.5%–8%.  This  is  compared  to  standard 
CABG mortality of less than 2%. In addition, LV 
dysfunction is a variable on standard scoring systems 
for assessing likely mortality such as the Euroscore/
Parsonnett  systems.5–8  There  are  suggestions  from 
non randomized observational data that patients with 
dysfunctional but viable myocardium are more likely 
to survive if they undergo revascularisation as opposed 
to medical therapy. Various imaging modalities have 
been proposed to detect viability, including nuclear 
techniques and cardiac magnetic resonance imaging 
(CMR).9  Each  technique  has  advantages,  some  of 
which are determined by patient characteristics. The 
identification  of  viable  dysfunctional  myocardium 
falsely  imaged  as  scar  is  a  concern  as  this  can 
adversely  influence  treatment  decisions.  This  is  a 
particular  problem  in  subjects  with  significant  left 
ventricular  dysfunction,  as  this  group  potentially 
have the most to gain from revascularisation10 and 
in whom perfusion and wall motion defects are most 
likely  to  be  present.  In  this  study,  we  report  our 
clinical experience in a group of patients referred for 
viability assessment who underwent testing with three 
commonly used imaging modalities,  99Tc-Sestamibi 
(MIBI),  18F-  flurodeoxyglucose  (FDG)  and  CMR, 
with a particular emphasis on the identification of 
scar by each imaging modality.
Methods
Subjects were referred for viability assessment if the 
assessing clinician felt that the patients might benefit 
from intervention for coronary artery disease in the 
context of clinical heart failure. Medical management 
was optimised and all were clinically stable prior with 
at  least  NYHA  class  II  symptomatic  heart  failure. 
Forty six patients were studied over a 24 month period. 
MR  scans  were  not  undertaken  in  4  subjects  with 
implanted devices (pacemakers or defibrillators) and 
3 were too large for the modified gamma camera. The 
images obtained from four of the FDG scans were not 
of diagnostic standard and were classed as technical 
failures such that complete data from all three imaging 
techniques was available for 35 patients. The baseline 
characteristics are shown in Table 1. Mean ejection 
fraction by MRI was 24% (median 23%) with a range 
of 10%–56%. Mean end diastolic volume was 200 ml 
with a range of 105–455 ml.
Assessments were undertaken on separate days 
according to the standard clinical protocol described 
Table 1. Patients’ baseline characteristics.
Age (mean ± sD) 70  ± 9
sex 29 males 6 females
Diabetes 2
Triple vessel disease 24
Two vessel disease 3
single vessel disease 4
Minor atheroma only 4
ejection fraction by Mri  
(mean ± sD)
24 ± 12%
ejection fraction by MiBi  
(mean ± sD)
33 ± 11%
Patients with documented  
prior Mi
16
  Within 6–12 months 5
  greater than 12 months 11
Body mass index 
(mean ± sD)
28 ± 3.8 kg/m2
Fasting blood glucose 
(mean ± sD)
6.1 ± 1.78 mmol/l
resting systolic blood  
pressure (mean ± sD)
141.8 ± 20.3 mmhg
resting diastolic blood  
pressure (mean ± sD)
85.8 ± 12.0 mmhgMyocardial scar assessment 
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below. None of the subjects reported a clinical event 
during the period of testing. The studies were reviewed 
by  at  least  two  cardiologists/  radiologists  blinded  to 
clinical data. A 20-segment model was used with 2 apical 
segments, and 3 radial layers of 6 segments at apical, 
mid and basal levels using short axis slices. This model 
was chosen as the software package for SPECT studies 
in our institution generates a 20 segment model and the 
AHA consensus statement supports a 20 segment model 
for this technique.11 Images were compared to determine 
agreement  between  areas  of  scar  identified  by  each 
technique.
sestamibi scanning
A  two-day  protocol  was  used  with  stress  and  rest 
scans at least 24 hours apart. Adenosine was used in 
the majority of cases as the stress agent at a dose of 
140 mcg/kg/min for a period of 6 minutes, with tracer 
being injected at 3 minutes. Dobutamine was used as 
an alternative stress agent in subjects with significant 
airways disease. Sublingual nitrates were administered 
in all cases prior to the isotope injection during the 
rest study. 99mTc MIBI (400 mBq) was administered 
for both the rest and the stress studies and images 
acquired with gated SPECT on a dual headed gamma 
camera (GE Millenium VG) at least 90 minutes post 
administration  of  radiopharmaceutical.  Acquisition 
was performed over a 360 degree arc using a standard 
parallel hole collimator. Subsequent data reconstruction 
and analysis was performed with QPS/QGS software 
(Cedars-Sinai, CA) for production of bulls-eye plots/
gated  EF  assessment  respectively,  on  a  dedicated 
Entegra workstation (GE Healthcare, UK). Ejection 
fraction  was  obtained  from  the  gated  rest  images. 
Viability was defined as uptake 60% of maximal 
pixel intensity on the resting image as described in 
the CHRISTMAS trial.12
18F-FDg scanning
Subjects  were  fasted  for  at  least  6  hours. 
A  hyperinsulinaemic  euglycaemic  clamp  was 
performed to standardise metabolic conditions and 
to  maximise  myocardial  18F-fluorodeoxyglucose 
(FDG)  uptake.  The  average  glucose  infusion  rate 
during  the  equilibrium  phase  of  the  clamp  was 
4.2+/-1.7  mg/kg/min.  At  least  80  minutes  after 
commencement  of   insulin  (during  clamp  steady 
state), FDG (185 MBq) was injected and scanning 
performed  30  minutes  after  injection  of  isotope. 
Images were acquired on the same gamma camera 
as the MIBI studies using high energy collimators 
to  facilitate  coincidence  mode,  and  corrected  for 
attenuation using X-rays. Images were analysed using 
an  Entegra  workstation  and  Cedars-Sinai  software 
(GE  medical  systems). A  segment  was  considered 
viable if uptake was 50% of the maximum pixel 
intensity.13
cMR
Patients were imaged using a 1.5T GE Signa CV/i 
scanner (GE Healthcare, UK) with a four channel 
cardiac phased array coil. Cine images were acquired 
by steady state free precession imaging in the short 
axis, 2 chamber and 4 chamber cardiac planes (slice 
thickness 10 mm, interslice gap 0–3 mm depending 
upon  length  of  ventricle).  Technical  parameters: 
TR 3.5, TE 1.3, flip angle 45 degrees, 0.75 NEX, 
matrix 224 × 128, FOV 36 × 36 cm, 75% phase field 
of view.
Viability imaging (“delayed enhancement”) was 
performed  10–30  minutes  following  a  total  bolus 
of 0.2 mmol/kg of gadolinium chelate (Omniscan, 
Amersham NJ) using an inversion recovery-prepared 
gradient echo pulse sequence. The optimal inversion 
time was individually adjusted for each patient. Images 
were acquired in matching locations to the cine images. 
Technical  parameters:  TR  7.2,  TE  3.2,  flip  angle 
15 degrees, matrix 256 × 192, trigger delay 500 msec, 
75% phase field of view, inversion time individually 
matched to patient (range 180–220 msec).
Polar viability maps were constructed based using 
the same 20 segment model as above, and viability 
defined as wall thickness 6 mm without delayed 
gadolinium  enhancement.14  In  areas  of  borderline 
wall thickness the segment was judged to be scar if 
the  transmural  extent  of  gadolinium  enhancement 
was 25%.15
Volumetric measurements from the MR data set 
were made by importing the short axis steady state 
free precession cine images into a dedicated off line 
workstation  with  appropriate  software  (Advantage 
Windows  4.2,  GE  Medical  Systems,  Milwaukee; 
Mass Analysis  Plus  5.2,  MEDIS  Medical  Imaging 
Systems, Nuenen, Netherlands).Crean et al
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statistical methods
Statistical  calculations  were  performed  using 
Statview 4.5 (Abacus Concepts, Berkeley, CA, USA). 
Numerical values are presented as mean +/- standard 
deviation. Comparisons between group means were 
carried out by analysis of variance (ANOVA). The 
agreement between the 3 imaging modalities to detect 
cardiac  scar  on  a  segment  by  segment  basis  was 
assessed using κ statistics. Κ values of less than 0.4, 
of 0.4 to 0.75 and greater than 0.75 were considered 
to  represent  poor,  moderate  to  good  and  excellent 
agreement  respectively  on  the  basis  of  the  Fleiss 
classification.16 A  p  value    0.05  was  considered 
statistically significant.
Results
The total number of scarred segments per patient for 
each imaging modality is shown in Table 2.
A significantly higher number of segments were 
identified as scar by MIBI than by either FDG or CMR. 
The over-estimation of scar by MIBI was independent 
of site within the left ventricle as shown in Table 3. 
For all modalities, apical segments were included in 
the anterior wall.
The best agreement between modalities was seen 
in the anterior wall with virtually no difference in the 
number of scar segments seen by MIBI, FDG and 
CMR. The worst agreement occurred in the inferior 
wall  with  an  87%  difference  between  MIBI  and 
FDG. An example of this discrepancy is shown in 
Figure 1(a), where MIBI imaging shows a large scar 
in the infero-lateral wall of the left ventricle which is 
absent on both FDG and CMR. Scar segments were 
seen most frequently in the inferior wall with MIBI 
scanning but in the anterior wall by both FDG and 
CMR. Concordant images with anteroseptal scar are 
shown in Figure 1(b).
The patients were divided into tertiles on the basis 
of resting ejection fraction determined from the gated 
MIBI  scan.  As  might  be  expected,  those  patients 
with  more  marked  left  ventricular  dysfunction 
demonstrated significantly more scar than those with 
more preserved ventricular function (Table 4). Again 
the discrepancy between amount of scar identified 
by the three modalities was maintained, except for 
patients  with  the  highest  ejection  fraction,  where 
CMR demonstrated least scar.
Discussion
There  is  an  increasing  evidence  base  to  support 
revascularisation in the context of viable ischaemic 
myocardium.17  Clinically  this  relies  on  the 
use  of  imaging  to  accurately  delineate  scarred 
(infarcted) myocardium from viable, non-functioning 
myocardium. Each of the imaging modalities used 
by our department is discussed in the recent report 
from  the  European  Society  of  Cardiology.9  Our 
results  would  suggest  that  there  is  considerable 
variation amongst these commonly used techniques. 
For clinical use in perfusion assessment, technetium 
based tracers are often preferred to thallium as these 
tracers  result  in  lower  radiation  exposure  to  the 
patient and a reduction in soft tissue attenuation.18 
However,  in  common  with  others  we  have  found 
that  MIBI  overestimates  areas  of  myocardial  scar 
tissue.19–24 Our patient cohort had moderate to severe 
left  ventricular  dysfunction  but  these  differences 
were seen across all tertiles of left ventricular function 
suggesting that increasing left ventricular impairment 
alone cannot account for the differences observed. 
Table 2. Comparison of scar burden between modalities.
Number of segments classified as scar
MIBI MRI FDG
7.4 ± 4.8 5.8 ± 5 4.9 ± 4.2
MIBI vs. MRI MIBI vs. FDG MRI vs. FDG
Difference in mean number   
of segments (95% Cis)
1.57 
(0.61–2.53)
2.46 
(1.27–3.64)
-0.89 
(-2.06 – 0.27)
P statistic p = 0.002 p = 0.0002 p = 0.13
Weighted kappa κ = 0.38 κ = 0.48 κ = 0.77Myocardial scar assessment 
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Technetium MIBI appeared to overestimate scar most 
frequently in the inferior LV segments, presumably 
as a result of diaphragmatic attenuation. Recent data 
has shown that attenuation correction can increase 
agreement  between  technetium  based  tracers  and 
FDG-SPECT,25 particularly when assessing viability 
in the infero-posterior wall. However, in our group of 
patients, differences were also found in the imaging of 
the lateral wall suggesting that this cannot completely 
explain these results. Our findings would bring into 
question the use of technetium MIBI to select subjects 
as having evidence of hibernation (for example as in 
the CHRISTMAS trial)12 as our data suggests that 
many  segments,  which  would  seem  to  be  scarred, 
are in fact viable by other imaging techniques. The 
over-reporting  of  scar  by  MIBI  is  unlikely  to  be 
explained solely by changes in perfusion at rest,26 as it 
is known that hibernating myocardium has preserved 
blood flow at rest.27 Reduced uptake/enhanced washout 
of technetium based tracers has been reported28,29 and 
it has been postulated that repetitive ischaemia might 
contribute to this.29 This mechanism is also thought to 
be important in chronic left ventricular dysfunction 
secondary to coronary artery disease30 and we believe 
Table 3. Average number of scar segments per patient 
according to the cardiac location.
   MIBI cMR FDG p
Anterior 2.1 +/- 1.9 2.0 +/- 1.9 2.0 +/- 1.7 0.6
septum 0.9 +/- 1.2 0.8 +/- 1.1 0.9 +/- 1.2 0.5
Lateral 1.6 +/- 1.6 1.1 +/- 1.4 0.6 +/- 1.1 0.0001
inferior 2.8 +/- 2.1 1.9 +/- 1.9 1.5 +/- 1.8 0.0001
Figure 1. Upper panel: a discordant study with inferior scar identified with MIBI, but viable myocardium with FDG and CMR (A–c). Lower panel: example 
of a concordant study with anterior scar identified with all three imaging modalities (D–F).
A B c
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that this may account for the some of the differences 
observed  here.  Based  on  these  results,  it  may  be 
prudent to consider alternatives to technetium MIBI 
in the assessment of myocardial viability.
There  is  a  relatively  close  agreement  between 
FDG  and  CMR  although  variation  exists  between 
these  two  modalities  that  may  reflect  the  limited 
spatial  resolution  and/or  partial  volume  effects 
associated  with  FDG  imaging  using  a  modified 
gamma camera that would tend to limit delineation of 
scar.31 Previous investigators have shown that visual 
analysis of MR has good correlation with quantitative 
analysis32 so we do not believe that this is solely a 
reflection of visual analysis although clearly image 
alignment with different imaging modalities remains 
a concern. Although there is numerical discrepancy 
in approximately half of all studies, clinical review 
of these patients suggests that this difference would 
have  altered  management  in  less  than  5  cases. 
The  discrepancy  is  unlikely  to  be  a  reflection  of 
the  FDG-SPECT  technique  per  se.  Only  2  out  of 
35 patients were diabetic and excellent suppression 
of  myocardial  FFA  utilisation  was  achieved  in  all 
patients  with  the  insulin  clamp  method.  Whilst 
preserved myocardial metabolic activity using FDG 
during hyperinsulinaemia is often regarded as the gold 
standard to assess viability, our findings suggest that 
there is no clinically significant difference between 
FDG  imaging  and  CMR  for  viability  assessment. 
We chose to define non viability at CMR primarily 
by  end  diastolic  wall  thickness  and  used  presence 
of  delayed  enhancement  as  a  secondary  criterion. 
This  is  because  there  remains  some  controversy 
about the exact degree to which trans-mural extent 
of scar identified by gadolinium correlates with non 
recoverability  of  function.  It  can  also  be  difficult 
to accurately delineate quartiles of transmurality in 
regions of severely thinned myocardium where an 
overall measurement of end diastolic wall thickness is 
potentially more reliable and reproducible. Although 
delayed enhancement at CMR may reflect uptake into 
an expanded interstitial space in addition to delayed 
washout  from  scar  following  acute  myocardial 
infarction, this consideration was not relevant to our 
sample since no patients were studied within 6 months 
of  an  acute  coronary  event  and  the  majority  were 
suffering from chronic ischaemic cardiomyopathy.
One aspect of this work requiring consideration 
is  the  homogeneity  of  our  patient  population. 
A small number of patients had minor atheroma or 
only  single  vessel  disease  raising  the  question  of 
whether they were incorrectly classified as ischaemic 
rather  than  dilated  cardiomyopathy.  However  it  is 
well  accepted  that  infarction  frequently  occurs  on 
low grade stenoses and a subendocardial pattern of 
infarction characteristic of coronary disease was seen 
by delayed enhancement CMR in all but one of these 
patients. The ability of CMR to distinguish between 
heart failure secondary to coronary disease from that 
due to other forms of cardiomyopathy has been well 
described  previously.33  Only  one  subject  displayed 
midwall septal enhancement without subendocardial 
enhancement elsewhere and we believe that this was 
an isolated case of idiopathic rather than ischaemic 
cardiomyopathy.
study limitations
In this study we used end diastolic wall thickness 
(EDWT) as our major determinant of viability by MRI. 
It is generally accepted that transmural extent of late 
gadolinium enhancement (LGE) is the gold standard 
for determining myocardial viability. However, the 
LGE technique is more challenging in the severely 
breathless heart failure patient due to altered blood 
pool kinetics and limited achievable spatial resolution 
(due to impaired patient breath hold ability) in areas 
of myocardial thinning. A navigated free-breathing 
approach to LGE image acquisition was discounted 
because of the length of time necessary to acquire a 
full volume data set in these enlarged left ventricles. 
Nonetheless EDWT is a reasonable surrogate that has 
been used many times in earlier literature and remains 
a valid measure.
The  limitations  of  this  study  also  include  the 
relatively small number of patients assessed and the 
Table 4. Average number of scar segments per patient 
according to ejection fraction.
eF 28% 28% 41%  41%
PeT 7.6 +/- 3.8 4.6 +/- 3.9 2.5 +/- 3.5
MiBi 73.2 +/- 3.0 7.5 +/- 4.7 3.2 +/- 3.0
CMr 6.3 +/- 4.61 6.3 +/- 4.6 1.2 +/- 2.3Myocardial scar assessment 
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lack of attenuation correction as discussed above. This 
is likely to increase the agreement between MIBI and 
the other imaging modalities but should not influence 
the  agreement  between  FDG-SPECT  and  CMR. 
This can only be clarified by defining the extent of 
functional  recovery  following  revascularisation, 
which we believe is the most significant limitation of 
this study.
In summary we present data obtained in a clinical 
service using three common imaging techniques in a 
group of patients. We suggest that technetium MIBI 
should  not  be  used  to  define  myocardial  viability 
where more accurate methods exist. Local resource 
availability  and  patient  characteristics  may  well 
dictate the use of FDG-PET or CMR and our data 
suggest that there is little practical difference between 
these two modalities.
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